Zercepac 150 mg Powder for concentrate for solution for infusion Vial

Zercepac 150 mg is a specialized medication presented as a powder for concentrate for solution for infusion, designed for the treatment of HER2-positive breast cancer and gastric cancer. As a biosimilar to trastuzumab, it works by targeting and blocking the HER2 protein found on the surface of some cancer cells, thereby inhibiting their growth and survival. This medication offers a crucial therapeutic option for eligible patients, contributing to improved outcomes when used as prescribed by a healthcare professional.

Benefits of Use

• Offers targeted therapy against HER2-positive cancer cells, minimizing impact on healthy cells.
• Clinically proven to be effective in treating certain types of breast cancer and metastatic gastric cancer.
• Can be used alone or in combination with other chemotherapy agents as prescribed by a healthcare professional.
• Contributes to improved patient outcomes in specific cancer treatment regimens.

How to Use

Zercepac 150 mg is a prescription-only medicine that must be administered under the supervision of a healthcare professional experienced in the treatment of oncology patients.

1. The powder in the vial is first reconstituted with sterile water for injection to form a concentrate.
2. This concentrate is then further diluted in an infusion bag containing sodium chloride solution.
3. The prepared solution is administered via intravenous infusion over a specified period, as determined by the treating physician.
4. Dosage and duration of treatment are individualized based on the patient's body weight and the specific cancer being treated.
5. Patients are monitored closely for any infusion-related reactions during and after administration.

Caution & Warnings

• Zercepac may cause serious infusion-related reactions, including chills, fever, nausea, vomiting, pain, headache, dizziness, and rash.
• Cardiac dysfunction, including heart failure, has been reported. Patients should undergo cardiac assessment before and during treatment.
• Pulmonary toxicity, such as dyspnea, cough, and interstitial pneumonitis, can occur.
• This medication must not be administered as an intravenous push or bolus.
• Not for self-administration. Always consult your doctor or pharmacist for specific medical advice.

Ingredients

• Active Ingredient: Trastuzumab 150 mg
• Excipients: L-histidine hydrochloride monohydrate, L-histidine, Sucrose, Polysorbate 20

Product Details

• Form: Powder for concentrate for solution for infusion
• Strength: 150 mg
• Administration Route: Intravenous infusion
• Manufacturer: Accord Healthcare
• Storage Conditions: Store in a refrigerator (2°C - 8°C). Keep the vial in the outer carton to protect from light. Do not freeze.